CN Patent

CN110621314A — 包含美洛昔康的药物组合物

Assigned to Aike Sam Therapeutics Inc · Expires 2019-12-27 · 6y expired

What this patent protects

本文公开了组合物，所述组合物包含药物诸如曲坦(例如利扎曲坦)和/或NSAID(例如美洛昔康)与环糊精和/或碳酸盐或碳酸氢盐的组合。这些组合物可以口服施用，例如以改善药物用于治疗诸如疼痛的病症的生物利用度或药代动力学。

USPTO Abstract

本文公开了组合物，所述组合物包含药物诸如曲坦(例如利扎曲坦)和/或NSAID(例如美洛昔康)与环糊精和/或碳酸盐或碳酸氢盐的组合。这些组合物可以口服施用，例如以改善药物用于治疗诸如疼痛的病症的生物利用度或药代动力学。

Drugs covered by this patent

Patent Metadata

Patent number
CN110621314A
Jurisdiction
CN
Classification
—
Expires
2019-12-27
Drug substance claim
No
Drug product claim
No
Assignee
Aike Sam Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.